Page 111 - GPD-3-3

Gene & Protein in Disease Exploring serum inflammatory biomarkers in GBM

the observation that IL-6’s increase may be mediated albumin, IL-6, VCAM-1, and TNF-α present valuable
by TNF-α, a marker that decreased in our analysis, targets for future investigation. The non-invasive nature
suggest that IL-6 could be a valuable target for studying of serum biomarker acquisition, coupled with appropriate
tumor resistance and GBM outcomes. If IL-6 emerges classification, holds the potential for elucidating biological
as a discriminating marker in relation to specific clinical mechanisms and their correlation with patient outcomes.
features, it could potentially be used to guide therapy Nevertheless, thorough evaluation is imperative to identify,
and personalize patient management. We hypothesize study, and enhance targeted management strategies.
that the discordant findings could be related to several The limitations of this analysis include its retrospective
factors: (i) the nature of the protein signal being measured nature, with patients diagnosed and treated over a span
in serum (as compared to in vitro or tissue samples of 20 years during which radiation oncology technology
employing mRNA expression or gene amplification with evolved, though clinical management may not have changed
91
the production of some markers lagging behind others) ; as significantly. Samples were collected over a prolonged
(ii) uncertainty about whether the signal originates from period, potentially affecting referral patterns, the extent
dead or live tumor cells ; (iii) the presence of related but or aggressiveness of surgical resection, and corticosteroid
88
distinct proteins that are not currently distinguishable in prescribing practices. In addition, the availability of
92
this study or published data ; and (iv) molecular tumor molecular features (MGMT and IDH status) was limited.
characterization and GBM heterogeneity, with distinct Despite these challenges, the observation of serum marker
resistance and response tumor subtypes, as observed alterations across all samples suggests considerable
in other cancers. The interaction between VCAM-1, independence from molecular status, although variability
93
IL-6, and CRP in this study revealed the potential for in baseline measurements and the extent of alteration may
subpopulations of patients, which may help explain the partially be attributable to molecular status. The selection
findings. Specifically, the duality of IL-6 increasing in some of markers from the literature search was carried out
patients and decreasing in others (Figure 4D) likely leads independently of our data; yet, it may still introduce bias,
to opposite downstream effects (Figure 6B).
as commonly published markers are often more readily
Overall, modulation of the STAT3 versus NF-κB measurable or accessible in electronic health records (e.g.,
balance toward either tumor resistance or response to CRP and albumin). Serum proteomic panels are rapidly
treatment might be measurable with serum biomarkers evolving to include an increasing number of proteins,
that are tumor-specific but may be more precisely defined thereby opening up the possibility of the identification of
when analyzed in conjunction with well-established serum novel markers with a limited footprint in the literature.
biomarkers, including CRP, albumin, and GFAP, which Capturing corticosteroid administration is particularly
are robustly captured in serum. These findings should be challenging, as patients receive varying doses at different
interpreted with caution, as it remains unclear whether times and undergo tapering before CRT initiation if
the signals measured in serum originate from live or dying neurological symptoms are controlled. Corticosteroids may
cells, or, more likely, a mixture of both. Future directions also be initiated during CRT with various dosing regimens,
should include the assessment of these markers in contingent on several factors, including the extent of
conjunction with clinical factors, including tumor burden initial resection, tumor location, tumor progression, and
and outcome endpoints, with validation in larger cohorts. response to radiation therapy. While steroid administration
At present, the use of APRs such as albumin, SAA, was examined in this study, the nuances of this factor are
and CRP in clinical monitoring is widespread despite difficult to fully define statistically, given the small number
their high non-specificity and associated challenges. 32,94 of patients in each category. Some molecules were noted
Ongoing research endeavors are focusing on establishing to have direct and indirect relationships to the time from
links between CRP and serum GFAP, and IL-6, which surgical intervention or to steroid administration. These
demonstrate promising potential for assessing brain relationships were not statistically significant but are
damage. 10,13,95 IL-6, in particular, has exhibited notable difficult to disentangle due to the confounding factors
diagnostic capabilities in pancreatic and gastric cancer, mentioned above.
96
with potential applications in treatment planning. 95,96 Validation with other datasets is highly challenging,
However, further investigation is needed to ascertain as serum proteomic datasets that capture more than
the suitability of serum levels of other markers, such as 1 time point in a homogenously treated histology are not
VCAM-1 and TNF-α, for treatment monitoring in human currently available. However, the current data can serve as a
models. 12,97 While the widespread adoption of these markers starting point for the exploration of circulating biomarkers
in clinical practice awaits additional research, SAA1, CRP, in GBM, potentially leading to improved experimental

Volume 3 Issue 3 (2024) 11 doi: 10.36922/gpd.3580